Three appointments at Calliditas

Calliditas Therapeutics AB
Appointee name
Maria Törnsén, Lars Stubberud and Brian Gorman


Calliditas Therapeutics AB of Sweden has made three appointments as it prepares for the commercialisation of its lead product Tarpeyo for the treatment of patients with IgAN nephropathy. Maria Törnsén has been named President North America where she will be responsible for all US-based operations. She was previously chief commercial officer at Passage Bio Inc. Lars Stubberud, previously head of pharmaceutical development and manufacturing at Calliditas, has been promoted to head of technical operations. Finally, Brian Gorman, formerly of Opiant Pharmaceuticals Inc, has joined the company as group general counsel.

The announcements were made on 1 December 2023 and 7 January 2024.

Copyright 2024 Evernow Publishing Ltd